Skip to textbook content
Doctor’s PassportTextbook
QuestionsFlashcardsBriefsDashboardAccount
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Induction of labour and cervical ripening

Obstetrics and gynaecology · UK scope · Sources checked 7 Sept 2026 · Clinical review pending

RapidFull
!
Excessive uterine activity or fetal compromise

Frequent or prolonged contractions during induction can reduce the interval for placental reperfusion and cause fetal compromise. Persistent pain, bleeding or maternal instability also requires assessment for rarer complications such as uterine rupture.

Action: Seek urgent midwifery and obstetric review, assess the fetal heart with cardiotocography and stop further induction medication or oxytocin. Remove a vaginal delivery system when possible, reposition away from supine and consider acute tocolysis. If fetal or maternal compromise persists, prepare to expedite birth.

Synopsis

Select an induction method from the indication, cervical assessment and uterine history, and recognise complications that require treatment to stop or the birth plan to change.

  • Induction starts labour artificially; cervical ripening prepares an unfavourable cervix and may be only the first step.
  • Explain why birth is proposed now, the alternatives, likely duration and how induction may affect the birth experience.
  • A Bishop score of 6 or less usually requires ripening; a score above 6 supports amniotomy with intravenous oxytocin.
  • NICE offers vaginal dinoprostone or low-dose 25-microgram oral misoprostol for an unfavourable cervix when suitable.
  • Consider a mechanical method when pharmacological ripening is unsuitable, hyperstimulation risk matters or the patient chooses it.
  • Previous uterine surgery materially changes risk and method selection; product contraindications must be checked rather than assuming all prostaglandins are interchangeable.
  • Failure of an initial attempt calls for reassessment and a shared plan, not automatic repetition of the same regimen.

Key red flags

Five or more contractions in ten minutes sustained for at least twenty minutes, or a prolonged contraction, requires prompt assessment rather than another induction dose.

A pathological fetal heart pattern, persistent bradycardia or new reduced fetal movements requires urgent review.

Constant pain between contractions, unusual bleeding or maternal cardiovascular deterioration requires assessment for an obstetric emergency.

A high or mobile presenting part at membrane rupture increases concern for cord prolapse.

Fever, rigors or offensive amniotic fluid requires assessment for infection and may alter the timing and route of birth.

Investigation priorities

01
Review of pregnancy records and ultrasound findingsFirst step

Confirm the indication and exclude important contraindications.

Management branches

Choosing the methodMatch treatment to the cervix and risk

Induction is agreed after assessment confirms that a vaginal birth pathway is appropriate.

  1. Explain available methods and their benefits, discomfort, monitoring requirements and risks, then obtain consent for the selected approach.
  2. For a Bishop score of 6 or less, offer suitable vaginal dinoprostone or low-dose oral misoprostol, checking the product's contraindications and administration instructions.
  3. Consider a balloon catheter or osmotic cervical dilator when pharmacological methods are unsuitable, including relevant scar or hyperstimulation concerns, or when the patient prefers a mechanical approach.
  4. For a Bishop score above 6, offer amniotomy and intravenous oxytocin. If the woman chooses to delay oxytocin, explain that labour may take longer and neonatal infection risk may increase.
  5. Document the planned reassessment, next step and route for obtaining urgent help if symptoms change.

Key medicines

Oral misoprostol, Angusta 25 microgram tabletsThe UK SmPC allows 25 micrograms orally every 2 hours or 50 micrograms every 4 hours, to a maximum of 200 micrograms in 24 hours. NICE specifies low-dose 25-microgram oral tablets as an induction option. Wait at least 4 hours after the last Angusta dose before oxytocin.Use the agreed maternity regimen with fetal and uterine monitoring. Do not continue once labour has started, with hyperstimulation or fetal concern, and check contraindications including previous uterine surgery. The swallowed dose cannot be retrieved if excessive activity develops.
Dinoprostone 10 mg vaginal delivery systemInsert one 10 mg controlled-release system according to the product instructions; it releases approximately 0.3 mg/hour over 24 hours. Remove after 24 hours, or sooner for the specified clinical removal criteria. The cited system requires at least 30 minutes between removal and oxytocin.Remove for established regular painful contractions, specified membrane-rupture circumstances, hyperstimulation or fetal concern. PROPESS specifies at least 30 minutes after removal before oxytocin, but the oxytocin SmPC cited in the augmentation chapter specifies six hours after vaginal prostaglandins. Maternity and pharmacy protocols must reconcile the actual products; the 30-minute interval cannot automatically be combined with that oxytocin preparation.
Open full textbook →Answer 2 questions
Sources and review status5 sources · checked 7 Sept 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 7 Sept 2026; clinical approval remains outstanding.

  • NICE NG207 inducing labour recommendations
  • Angusta oral misoprostol product characteristics
  • Dinoprostone vaginal delivery system product characteristics
  • NICE NG229 management of intrapartum fetal concerns
  • Oxytocin product information and prostaglandin interval

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom